Copyright © 2001 by the European Society of Cardiology.
Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function
Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, U.K.
revised November 7, 2000; accepted November 8, 2000
Abstract
Background Atrial fibrillation is associated with increased risk of stroke and thromboembolism, possibly by conferring a prothrombotic or hypercoagulable state. However, it is unclear whether or not this differs in the clinical subgroups of chronic atrial fibrillation patients, that is, in those with paroxysmal, persistent or permanent atrial fibrillation. We therefore hypothesized that: (i) there are differences in the prothrombotic state between these patients; and (ii) reduction in indices of hypercoagulability would follow elective electrical cardioversion of persistent atrial fibrillation and the return of left atrial function.
Patients and Methods We studied 69 patients with chronic atrial fibrillation: 23 with paroxysmal atrial fibrillation (16 males; mean age 65 years±SD13); 23 with persistent atrial fibrillation (16 males; 65 years±13), with a mean duration of atrial fibrillation of 3 months (range 2 to 6 months); and 23 with permanent atrial fibrillation (16 males; 67 years±10). Blood results were compared to 20 age- and sex-matched healthy controls. The patients with persistent atrial fibrillation then underwent elective DC cardioversion, with Doppler echocardiographic examinations and bloods tests performed prior to cardioversion, and at 3 and 12 weeks afterwards. The prothrombotic state was quantified by measurement of plasma levels of fibrinogen, soluble P-selectin (an index of platelet activation) and von Willebrand factor (a marker of endothelial dysfunction).
Results Permanent atrial fibrillation was associated with significantly raised levels of von Willebrand factor, soluble P-selectin and fibrinogen (all P<0·001); paroxysmal atrial fibrillation with significantly elevated levels of plasma von Willebrand factor (P=0·0067) and fibrinogen (P=0·0001) but not soluble P-selectin (P=0·472); and persistent atrial fibrillation with normal levels of fibrinogen, von Willebrand factor and soluble P-selectin when compared to healthy controls (all P=ns). Stepwise multiple regression analyses demonstrated that the presence of atrial fibrillation was an independent predictor of abnormal von Willebrand factor, fibrinogen and soluble P-selectin levels. Electrical cardioversion of the patients with persistent atrial fibrillation did not significantly alter levels of von Willebrand factor (P=0·766), soluble P-selectin (P=0·726) or fibrinogen (P=0·50) despite maintenance of sinus rhythm and a significant return of left atrial systolic function (as quantified by the presence of A wave on Doppler echocardiography) at 3 months.
Conclusion There were significant differences in the prothrombotic state when patients with paroxysmal and permanent atrial fibrillation are compared to matched patients with persistent atrial fibrillation or controls in sinus rhythm. Cardioversion of persistent atrial fibrillation did not significantly alter indices of hypercoagulability even after 3 months maintenance of sinus rhythm, despite the return of atrial systole.
Key Words: Atrial fibrillation, electrical cardioversion, haemostatic markers, left atrial function
f1 Correspondence: Dr G. Y. H. Lip, Haemostasis Thrombolis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, U.K.
References
- Wolf PA, Dawber TR, Thomas E Jr, Kannel WB. Epidemiological assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28:973–977
[Abstract/Free Full Text] - Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol. 1996;77:24A–37A[CrossRef][Medline]
- Lip GYH. How would I manage a 60 year old woman presenting with atrial fibrillation? Proceedings of the Royal College of Physicians of Edinburgh. 1999;29:301–306
- Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol. 1992;19:851–855[Abstract]
- Laupacis A, Albers G, Dalen J, Dunn M, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114:579S–589S[ISI][Medline]
- Manning WJ, Silverman DI, Katz SE. Impaired left atrial mechanical function after cardioversion: relationship to the duration of atrial fibrillation. J Am Coll Cardiol. 1994;23:1535–1540[Abstract]
- Daoud EG, Marcovitz P, Knight BP. Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation. 1999;99:3024–3027
[Abstract/Free Full Text] - Oltrona L, Broccolino M, Merlini PA, Spinola A, Pezzano A, Mannucci PM. Activation of the haemostatic mechanism after pharmacological cardioversion of acute nonvalvular atrial fibrillation. Circulation. 1997;95:2003–2006
[Abstract/Free Full Text] - Lip GYH, Rumley A, Dunn FG, Lowe GD. Plasma fibrinogen and fibrin D-dimer levels in atrial fibrillation: effect of cardioversion to sinus rhythm. Int J Cardiol. 1995;51:245–253[CrossRef][ISI][Medline]
- Blann AD, Lip GYH. The endothelium in cardiovascular disease: Functions, assessment and implications. Blood Coag and Fibrinol. 1998;9:297–306
- Lip GYH. Fibrinogen and cardiovascular disease. QJM. 1995;88:155–165
[Abstract/Free Full Text] - Blann AD, Lip GYH. Is soluble P-selectin a new marker of platelet activation? Atherosclerosis. 1997;128:135–138[CrossRef][ISI][Medline]
- Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin therapy. Br Heart J. 1995;73:527–533
[Abstract/Free Full Text] - Pernerstorfer T, Stohlawetz P, Stummvoll G, Kapiotis S, Szekeres T, Eichler H-G, Jilma B. Low dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haem. 1998;102:1229–1231[CrossRef][ISI][Medline]
- Lip GYH. Does atrial fibrillation confer a hypercoagulable state? Lancet. 1995;346:1313–1314[CrossRef][ISI][Medline]
- Lip GYH. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk? Lancet. 1997;349:1565–1566[CrossRef][ISI][Medline]
- Lip GYH, Lowe GDO, Rumley A, Dunn F. Plasma fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence of intermediate levels of intravascular thrombogenesis. Am Heart J. 1996;131:724–730[CrossRef][ISI][Medline]
- Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol. 1997;29:106–112[Abstract]
- Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in nonrheumatic atrial fibrillation. Heart. 1997;77:407–411
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. G. Akar, W. Jeske, and D. J. Wilber Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1790 - 1793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Nieuwlaat, T. Dinh, S. B. Olsson, A. J. Camm, A. Capucci, R. G. Tieleman, G. Y.H. Lip, H. J.G.M. Crijns, and on behalf of the Euro Heart Survey Investigators Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur. Heart J., April 1, 2008; 29(7): 915 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Duygu, V. Barisik, H. Kurt, U. Turk, E. Ercan, and S. Kose Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation Europace, February 1, 2008; 10(2): 210 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Freestone, A. Y. Chong, S. Nuttall, A. D. Blann, and G. Y. H. Lip Soluble E-selectin, von Willebrand Factor, Soluble Thrombomodulin, and Total Body Nitrate/Nitrite Product as Indices of Endothelial Damage/Dysfunction in Paroxysmal, Persistent, and Permanent Atrial Fibrillation Chest, October 1, 2007; 132(4): 1253 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Choudhury, I. Chung, A. D. Blann, and G. Y.H. Lip Platelet Surface CD62P and CD63, Mean Platelet Volume, and Soluble/Platelet P-Selectin as Indexes of Platelet Function in Atrial Fibrillation: A Comparison of "Healthy Control Subjects" and "Disease Control Subjects" in Sinus Rhythm J. Am. Coll. Cardiol., May 15, 2007; 49(19): 1957 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Choudhury, I. Chung, A. D. Blann, and G. Y. H. Lip Elevated Platelet Microparticle Levels in Nonvalvular Atrial Fibrillation: Relationship to P-Selectin and Antithrombotic Therapy Chest, March 1, 2007; 131(3): 809 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rotter, P. Jais, M.-C. Vergnes, P. Nurden, Y. Takahashi, P. Sanders, T. Rostock, M. Hocini, F. Sacher, and M. Haissaguerre Decline in C-Reactive Protein After Successful Ablation of Long-Lasting Persistent Atrial Fibrillation J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1231 - 1233. [Full Text] [PDF]
|
|
|
|
|
|
C. J. Boos, R. A. Anderson, and G. Y.H. Lip Is atrial fibrillation an inflammatory disorder? Eur. Heart J., January 2, 2006; 27(2): 136 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Marin, V Roldan, V E Climent, A Ibanez, A Garcia, P Marco, F Sogorb, and G Y H Lip Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation Heart, October 1, 2004; 90(10): 1162 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip Relationship of interleukin-6 and C-Reactive protein to the prothrombotic state in chronic atrial fibrillation J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2075 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Mathew, M. L. Fontes, I. C. Tudor, J. Ramsay, P. Duke, C. D. Mazer, P. G. Barash, P. H. Hsu, and D. T. Mangano A Multicenter Risk Index for Atrial Fibrillation After Cardiac Surgery JAMA, April 14, 2004; 291(14): 1720 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Kamath, A D Blann, B S P Chin, and G Y H Lip Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a comparison with permanent atrial fibrillation Heart, September 1, 2003; 89(9): 1093 - 1095. [Full Text] [PDF]
|
|
|
|
 |
|
 N. A.Y. Chung, F. Belgore, F. L. Li-Saw-Hee, D. S.G. Conway, A. D. Blann, and G. Y.H. Lip Is the Hypercoagulable State in Atrial Fibrillation Mediated by Vascular Endothelial Growth Factor? Stroke, September 1, 2002; 33(9): 2187 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kamath, A. D. Blann, G. J. Caine, D. Gurney, B. S.P. Chin, and G. Y.H. Lip Platelet P-Selectin Levels in Relation to Plasma Soluble P-Selectin and {beta}-Thromboglobulin Levels in Atrial Fibrillation Stroke, May 1, 2002; 33(5): 1237 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.Y.H. Lip and F.L. L. S. Hee Paroxysmal atrial fibrillation QJM, December 1, 2001; 94(12): 665 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.M. Al-Saady and M. Sopher Prothrombotic markers in atrial fibrillation: what is new? Eur. Heart J., September 2, 2001; 22(18): 1635 - 1639. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||